Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Invested Capital (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Invested Capital for 8 consecutive years, with $618.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital fell 25.58% year-over-year to $618.5 million, compared with a TTM value of $618.5 million through Sep 2025, down 25.58%, and an annual FY2024 reading of $793.1 million, up 113.8% over the prior year.
  • Invested Capital was $618.5 million for Q3 2025 at Bicycle Therapeutics, down from $668.9 million in the prior quarter.
  • Across five years, Invested Capital topped out at $896.2 million in Q2 2024 and bottomed at $142.0 million in Q2 2021.
  • Average Invested Capital over 5 years is $429.3 million, with a median of $346.3 million recorded in 2021.
  • The sharpest move saw Invested Capital dropped 29.32% in 2023, then soared 307.19% in 2024.
  • Year by year, Invested Capital stood at $346.3 million in 2021, then fell by 21.8% to $270.8 million in 2022, then skyrocketed by 36.98% to $370.9 million in 2023, then skyrocketed by 113.8% to $793.1 million in 2024, then dropped by 22.01% to $618.5 million in 2025.
  • Business Quant data shows Invested Capital for BCYC at $618.5 million in Q3 2025, $668.9 million in Q2 2025, and $740.3 million in Q1 2025.